{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:16:20Z","timestamp":1790615780589,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,8,30]],"date-time":"2015-08-30T00:00:00Z","timestamp":1440892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00223-015-0052-z","type":"journal-article","created":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T06:23:28Z","timestamp":1440829408000},"page":"341-358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures"],"prefix":"10.1007","volume":"98","author":[{"given":"E. F.","family":"Nemeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,30]]},"reference":[{"key":"52_CR1","doi-asserted-by":"crossref","first-page":"EP101","DOI":"10.1016\/B978-0-12-397166-1.00006-0","volume-title":"The parathyroids","author":"EM Brown","year":"2015","unstructured":"Brown EM (2015) Control of parathyroid hormone secretion by its key physiological regulators. In: Bilezikian JP, Marcus R, Levine MA, Marcocci C, Silverberg SJ, Potts JT (eds) The parathyroids, 3rd edn. Elsevier, Amsterdam, pp EP101\u2013EP118","edition":"3"},{"key":"52_CR2","first-page":"F485","volume":"298","author":"D Riccardi","year":"2010","unstructured":"Riccardi D, Brown EM (2010) Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol 298:F485\u2013F499","journal-title":"Am J Physiol"},{"key":"52_CR3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrendo.2015.30","volume":"11","author":"D Goltzman","year":"2015","unstructured":"Goltzman D, Hendy GN (2015) The calcium-sensing receptor in bone\u2014mechanistic and therapeutic insights. Nat Rev Endocrinol Metab 11:298\u2013307","journal-title":"Nat Rev Endocrinol Metab"},{"key":"52_CR4","first-page":"752","volume":"16","author":"F Raue","year":"1995","unstructured":"Raue F, Scher\u00fcbl H (1995) Extracellular calcium sensitivity and voltage-dependent calcium channels in C-cells. Endocr Rev 16:752\u2013764","journal-title":"Endocr Rev"},{"key":"52_CR5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/ncpendmet0388","volume":"3","author":"EM Brown","year":"2007","unstructured":"Brown EM (2007) Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocr Metab 3:122\u2013133","journal-title":"Nat Clin Pract Endocr Metab"},{"key":"52_CR6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.beem.2013.04.007","volume":"27","author":"FM Hannan","year":"2013","unstructured":"Hannan FM, Thakker RV (2013) Calcium-sensing receptor (CaSR) mutations and disorders of calcium, electrolyte and water metabolism. Best Prac Res Clin Endocr Metab 27:359\u2013371","journal-title":"Best Prac Res Clin Endocr Metab"},{"key":"52_CR7","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.ddtec.2012.11.002","volume":"10","author":"EF Nemeth","year":"2013","unstructured":"Nemeth EF (2013) Allosteric modulators of the extracellular calcium receptor. Drug Disc Today Technol 10:e273\u2013e284","journal-title":"Drug Disc Today Technol"},{"key":"52_CR8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1196\/annals.1346.044","volume":"1068","author":"EF Nemeth","year":"2006","unstructured":"Nemeth EF (2006) Misconceptions about calcimimetics. Ann NY Acad Sci 1068:471\u2013476","journal-title":"Ann NY Acad Sci"},{"key":"52_CR9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4155\/fmc.11.17","volume":"3","author":"L Widler","year":"2011","unstructured":"Widler L (2011) Calcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis. Future Med Chem 3:535\u2013547","journal-title":"Future Med Chem"},{"key":"52_CR10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0022-3565(24)34925-0","volume":"290","author":"J Fox","year":"1999","unstructured":"Fox J, Lowe SH, Conklin RL, Petty BA, Nemeth EF (1999) Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca2+ receptor in rats. J Pharmacol Exp Ther 290:480\u2013486","journal-title":"J Pharmacol Exp Ther"},{"key":"52_CR11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","volume":"308","author":"EF Nemeth","year":"2004","unstructured":"Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308:627\u2013635","journal-title":"J Pharmacol Exp Ther"},{"key":"52_CR12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2125.2004.02088.x","volume":"57","author":"N Ohashi","year":"2004","unstructured":"Ohashi N, Uematsu T, Nagashima S, Kanamaru M, Togawa A, Hishida A, Uchida E, Akizawa T, Koshikawa S (2004) The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol 57:726\u2013734","journal-title":"Br J Clin Pharmacol"},{"key":"52_CR13","first-page":"1339","volume-title":"Principles of bone biology","author":"EF Nemeth","year":"1996","unstructured":"Nemeth EF (1996) Calcium receptors as novel drug targets. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology. Academic Press, New York, pp 1339\u20131359"},{"key":"52_CR14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0143-4160(90)90033-Q","volume":"11","author":"EF Nemeth","year":"1990","unstructured":"Nemeth EF (1990) Regulation of cytosolic calcium by extracellular divalent cations in C-cells and parathyroid cells. Cell Calcium 11:323\u2013327","journal-title":"Cell Calcium"},{"key":"52_CR15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.beem.2013.02.008","volume":"27","author":"EF Nemeth","year":"2013","unstructured":"Nemeth EF, Shoback D (2013) Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders. Best Prac Res Clin Endocr Metab 27:373\u2013384","journal-title":"Best Prac Res Clin Endocr Metab"},{"key":"52_CR16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","volume":"90","author":"M Peacock","year":"2005","unstructured":"Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocr Metab 90:135\u2013141","journal-title":"J Clin Endocr Metab"},{"key":"52_CR17","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","volume":"94","author":"M Peacock","year":"2009","unstructured":"Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheny S, Shoback D (2009) Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitomertric outcomes in a five-year study. J Clin Endocr Metab 94:4860\u20134867","journal-title":"J Clin Endocr Metab"},{"key":"52_CR18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/med\/9780199559176.003.026","volume-title":"The spectrum of mineral and bone disorders in chronic kidney disease","author":"EF Nemeth","year":"2010","unstructured":"Nemeth EF (2010) Calcimimetics and calcilytics in the treatment of chronic kidney disease-mineral bone disorder. In: Olgaard K, Salusky IB, Silver J (eds) The spectrum of mineral and bone disorders in chronic kidney disease, 2nd edn. Oxford University Press, Oxford, pp 443\u2013461","edition":"2"},{"key":"52_CR19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/kisup.2013.90","volume":"3","author":"TB Dr\u00fceke","year":"2013","unstructured":"Dr\u00fceke TB (2013) Calcimimetics and outcomes in CKD. Kidney Intl Suppl 3:431\u2013435","journal-title":"Kidney Intl Suppl"},{"key":"52_CR20","doi-asserted-by":"crossref","first-page":"c124","DOI":"10.1159\/000345164","volume":"121","author":"K Cooper","year":"2012","unstructured":"Cooper K, Quarles D, Kubo Y, Tomlin H, Goodman W (2012) Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients. Nephron Clin Pract 121:c124\u2013c130","journal-title":"Nephron Clin Pract"},{"key":"52_CR21","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, De Francisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Dr\u00fceke T, Goodman WG (2004) The calcimimetic cinacalcet hydrochloride for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516\u20131525","journal-title":"N Engl J Med"},{"key":"52_CR22","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","volume":"119","author":"OM Gutierrez","year":"2009","unstructured":"Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545\u20132552","journal-title":"Circulation"},{"key":"52_CR23","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:2432\u20132439","journal-title":"JAMA"},{"key":"52_CR24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MNH.0b013e328303e172","volume":"17","author":"H Galitzer","year":"2008","unstructured":"Galitzer H, Ben-Dov I, Lavi-Moshayoff V, Naveh-Many T, Silver J (2008) Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion. Curr Opin Nephrol Hypertens 17:363\u2013367","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"52_CR25","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1210\/en.2013-1627","volume":"154","author":"V David","year":"2013","unstructured":"David V, Dai B, Martin A, Huang J, Han X, Quarles LD (2013) Calcium regulates FGF-23 expression in bone. Endocrinology 154:4469\u20134482","journal-title":"Endocrinology"},{"key":"52_CR26","author":"JB Wetmore","year":"2015","unstructured":"Wetmore JB, Gurevich K, Sprague S, DaRoza G, Buerkert J, Reiner M, Goodman W, Cooper K (2015) A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. doi: 10.2215\/CJN.07050714","journal-title":"Clin J Am Soc Nephrol"},{"key":"52_CR27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","volume":"5","author":"JB Wetmore","year":"2010","unstructured":"Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD (2010) Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 5:110\u2013116","journal-title":"Clin J Am Soc Nephrol"},{"key":"52_CR28","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"GM Chertow","year":"2012","unstructured":"Chertow GM, Block GA, Correa-Rotter R, Dr\u00fceke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482\u20132494","journal-title":"N Engl J Med"},{"issue":"1","key":"52_CR29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","volume":"132","author":"SM Moe","year":"2015","unstructured":"Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Dr\u00fceke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J (2015) Cinacalcet, FGF23 and cardiovascular disease in hemodialysis: the EVOLVE trial. Circulation 132(1):27\u201339","journal-title":"Circulation"},{"issue":"Suppl 1","key":"52_CR30","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1111\/j.1744-9987.2008.00630.x","volume":"12","author":"A Yajima","year":"2008","unstructured":"Yajima A, Akizawa T, Tsukamoto Y, Kurihara S, Ito A (2008) Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism. Ther Apher Dial 12(Suppl 1):S38\u2013S43","journal-title":"Ther Apher Dial"},{"key":"52_CR31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5414\/CNP69269","volume":"69","author":"HH Malluche","year":"2008","unstructured":"Malluche HH, Monier-Faugere MC, Wang G, Fraza OJM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG (2008) An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69:269\u2013278","journal-title":"Clin Nephrol"},{"key":"52_CR32","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","volume":"87","author":"GJ Behets","year":"2015","unstructured":"Behets GJ, Spasovski G, Sterling LR, Goodman WG, Spiegel DM, De Broe ME, D\u2019Haese PC (2015) Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87:846\u2013856","journal-title":"Kidney Int"},{"key":"52_CR33","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","volume":"26","author":"SM Moe","year":"2015","unstructured":"Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Dr\u00fceke TB (2015) Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol 26:1466\u20131475","journal-title":"J Am Soc Nephrol"},{"key":"52_CR34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1681\/ASN.2004020138","volume":"16","author":"RN Foley","year":"2005","unstructured":"Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ (2005) The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 16:210\u2013218","journal-title":"J Am Soc Nephrol"},{"key":"52_CR35","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1210\/endo.139.10.6262","volume":"139","author":"YC Li","year":"1998","unstructured":"Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, Delling G, Demay MB (1998) Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocr 139:4391\u20134396","journal-title":"Endocr"},{"key":"52_CR36","first-page":"F1192","volume":"297","author":"T Meir","year":"2009","unstructured":"Meir T, Levi R, Lieben L, Libutti S, Carmeliet G, Bouillon R, Silver J, Naveh-Many T (2009) Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the receptor in parathyroid physiology. Am J Physiol 297:F1192\u2013F1198","journal-title":"Am J Physiol"},{"key":"52_CR37","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/ndt\/gfh924","volume":"20","author":"AE Kruse","year":"2005","unstructured":"Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG (2005) The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 20:1311\u20131314","journal-title":"Nephrol Dial Transplant"},{"key":"52_CR38","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/ndt\/gfh925","volume":"20","author":"AL Serra","year":"2005","unstructured":"Serra AL, Schwarz AA, Wick FH, Marti HP, Wuthrich RP (2005) Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 20:1315\u20131319","journal-title":"Nephrol Dial Transplant"},{"key":"52_CR39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/TP.0b013e31817c13e1","volume":"86","author":"C Bergua","year":"2008","unstructured":"Bergua C, Torregrosa JV, Fuster D, Gutierrez-Dalmau A, Oppenheimer F, Campistol JM (2008) Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplant 86:413\u2013417","journal-title":"Transplant"},{"key":"52_CR40","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/ajt.12911","volume":"14","author":"P Evenepoel","year":"2014","unstructured":"Evenepoel P, Cooper K, Holdaas CH, Messa P, Mourad G, Olgaard K, Rutkowski B, Schaefer H, Deng H, Torregrosa JV, Wuthrich RP, Yue S (2014) A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant 14:2545\u20132555","journal-title":"Am J Transplant"},{"key":"52_CR41","doi-asserted-by":"crossref","unstructured":"Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, Deng H, Yue S, Vincenti F (2015) A prospective cohort study of mineral Metabolism After Kidney transplantation. Transplantation. doi: 10.1097\/TP.0000000000000823","DOI":"10.1097\/TP.0000000000000823"},{"key":"52_CR42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","volume":"346","author":"S Walter","year":"2013","unstructured":"Walter S, Baruch A, Dong J, Tomilnson Alexander ST, Janes J, Hunter T, Yin Q, Maclean D, Bell G, Mendel DB, Johnson RM, Karim F (2013) Pharmacology of AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther 346:229\u2013240","journal-title":"J Pharmacol Exp Ther"},{"key":"52_CR43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2369-15-81","volume":"15","author":"S Walter","year":"2014","unstructured":"Walter S, Baruch A, Alexander ST, Janes J, Sho E, Dong J, Yin Q, Maclean D, Mendel DB, Karim F, Johnson RM (2014) Comparison of AMG 416 and cinacalcet in rodent models of uremia. BMC Nephrol 15:81\u201386","journal-title":"BMC Nephrol"},{"key":"52_CR44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","volume":"85","author":"KJ Martin","year":"2013","unstructured":"Martin KJ, Pickthorn K, Huang S, Block GA, Vick A, Mount PF, Power DA, Bell G (2013) AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Intl 85:191\u2013197","journal-title":"Kidney Intl"},{"key":"52_CR45","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1185\/03007995.2015.1031731","volume":"31","author":"G Bell","year":"2015","unstructured":"Bell G, Huang S, Martin KJ, Block GA (2015) A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for thre treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin 31:943\u2013952","journal-title":"Curr Med Res Opin"},{"key":"52_CR46","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/jcph.460","volume":"55","author":"P Chen","year":"2015","unstructured":"Chen P, Melhem M, Xiao J, Kuchimanchi M, Perez Ruixo JJ (2015) Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. J Clin Pharmacol 55:620\u2013628","journal-title":"J Clin Pharmacol"},{"key":"52_CR47","unstructured":"Amgen press release http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?year=2014&releaseID=1948573"},{"key":"52_CR48","unstructured":"Amgen press release http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?year=2014&releaseID=1959215"},{"key":"52_CR49","unstructured":"Amgen press release http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?year=2015&releaseID=2020209"},{"key":"52_CR50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coph.2015.03.005","volume":"22","author":"BC Silve","year":"2015","unstructured":"Silve BC, Bilezikian JP (2015) Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol 22:41\u201350","journal-title":"Curr Opin Pharmacol"},{"key":"52_CR51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-397166-1.00004-7","volume-title":"The parathyroids","author":"TJ Gardella","year":"2015","unstructured":"Gardella TJ (2015) Interations of PTH with receptors and signaling. In: Bilezikian JP, Marcus R, Levine MA, Marcocci C, Silverberg SJ, Potts JT (eds) The parathyroids, 3rd edn. Elsevier, Amsterdam, pp 65\u201380","edition":"3"},{"key":"52_CR52","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, O\u2019Dea LSTL, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G (2014) Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. doi: 10.1210\/jc.2014-3718","journal-title":"J Clin Endocrinol Metab"},{"key":"52_CR53","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1138\/20080318","volume":"5","author":"EF Nemeth","year":"2008","unstructured":"Nemeth EF (2008) Anabolic therapy for osteoporosis: calcilytics. IBMS BoneKEy 5:196\u2013208","journal-title":"IBMS BoneKEy"},{"key":"52_CR54","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1172\/JCI9038","volume":"105","author":"M Gowen","year":"2000","unstructured":"Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J (2000) Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 105:1595\u20131604","journal-title":"J Clin Invest"},{"key":"52_CR55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bone.2011.04.007","volume":"49","author":"MR John","year":"2011","unstructured":"John MR, Widler L, Gamse R, Buhl T, Seuwen K, Breitenstein W, Bruin GJM, Belleli R, Klickstein LR, Kneissel M (2011) ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone 49:233\u2013241","journal-title":"Bone"},{"key":"52_CR56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejphar.2011.07.015","volume":"668","author":"S Kimura","year":"2011","unstructured":"Kimura S, Nakagawa T, Matsuo Y, Ishida Y, Okamoto Y, Hayashi M (2011) JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats. Eur J Pharmacol 668:331\u2013336","journal-title":"Eur J Pharmacol"},{"key":"52_CR57","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.bone.2012.03.004","volume":"50","author":"JE Fisher","year":"2012","unstructured":"Fisher JE, Scott K, Wei N, Zhao JZ, Cusick T, Tijerina M, Karanam B, Duong L, Glantschnig H (2012) Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305\/MK-5442 and alendronate in osteopenic ovariectomized rats. Bone 50:1332\u20131342","journal-title":"Bone"},{"key":"52_CR58","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bone.2009.09.028","volume":"46","author":"S Kumar","year":"2010","unstructured":"Kumar S, Matheny CJ, Hoffman SJ, Marquis RW, Schultz Liang X, Vasko J, Stroup GB, Vaden VR, Haley H, Fox J, DelMar EJ, Nemeth EF et al (2010) An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 46:534\u2013542","journal-title":"Bone"},{"key":"52_CR59","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bone.2014.04.015","volume":"64","author":"MR John","year":"2014","unstructured":"John MR, Harfst E, L\u00f6effler J, Belleli R, Mason J, Bruin GJM, Seuwen K, Klickstein LB, Mindelholm Widler L, Kneissel M (2014) AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. Bone 64:204\u2013210","journal-title":"Bone"},{"key":"52_CR60","doi-asserted-by":"crossref","first-page":"E2207","DOI":"10.1210\/jc.2013-4009","volume":"99","author":"J Halse","year":"2014","unstructured":"Halse J, Greenspan S, Cosman F, Ellis G, Santora A, Leung A, Heyden N, Samanta S, Doleckyj S, Rosenberg E, Denker AE (2014) A Phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis. J Clin Endocrinol Metab 99:E2207\u2013E2215","journal-title":"J Clin Endocrinol Metab"},{"key":"52_CR61","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1210\/jc.2010-2855","volume":"96","author":"LA Fitzpatrick","year":"2011","unstructured":"Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG III, Bilezikian JP (2011) The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 96:2441\u20132449","journal-title":"J Clin Endocrinol Metab"},{"key":"52_CR62","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/jbmr.554","volume":"27","author":"LA Fitzpatrick","year":"2012","unstructured":"Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Fuerst T, Engelke K, Genant HK (2012) Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Min Res 27:255\u2013262","journal-title":"J Bone Min Res"},{"key":"52_CR63","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bone.2011.06.017","volume":"49","author":"LA Fitzpatrick","year":"2011","unstructured":"Fitzpatrick LA, Smith PL, McBride TA, Fries MA, Hossain M, Dabrowski CE, Gordon DN (2011) Ronacaleret, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: results of a randomized, double-blinded, placebo-controlled Phase II clinical trial. Bone 49:845\u2013852","journal-title":"Bone"},{"key":"52_CR64","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bone.2013.05.021","volume":"56","author":"S Caltabiano","year":"2013","unstructured":"Caltabiano S, Dollery CT, Hossain M, Kurtinecz MF, Desjardins JP, Favus MJ, Kumar R, Fitzpatrick LA (2013) Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women. Bone 56:154\u2013162","journal-title":"Bone"},{"key":"52_CR65","first-page":"E841","volume":"302","author":"Y Xue","year":"2012","unstructured":"Xue Y, Xiao Y, Liu J, Karaplis AC, Pollak MR, Brown EM, Mino D, Goltzman D (2012) The calcium-sensing receptor supplements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice. Am J Physiol 302:E841\u2013E851","journal-title":"Am J Physiol"},{"key":"52_CR66","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1073\/pnas.0306141101","volume":"101","author":"MM Dvorak","year":"2004","unstructured":"Dvorak MM, Siddiqua A, Ward DT, Carter DH, Dallas SL, Nemeth EF, Riccardi D (2004) Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc Natl Acad Sci 101:5140\u20135145","journal-title":"Proc Natl Acad Sci"},{"key":"52_CR67","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/hmg\/dds105","volume":"21","author":"FM Hannan","year":"2012","unstructured":"Hannan FM, Nesbit MA, Zhang C, Cranston T, Curley AJ, Harding B, Fratter C, Rust N, Christie PT, Turner JJO, Lemos MC, Bowl MR, Bouillon R, Brain C, Bridges N, Burren C, Connell JM, Jung H, Marks E, McCredie D, Mughal Z, Rodda C, Tollefsen S, Brown EM, Yang JJ, Thakker RV (2012) Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum Mol Gen 21:2768\u20132778","journal-title":"Hum Mol Gen"},{"key":"52_CR68","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1056\/NEJMoa1300253","volume":"368","author":"MA Nesbit","year":"2013","unstructured":"Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T, Rust N, Hobbs MR, Heath H III, Thakker RV (2013) Mutations affecting G-protein subunit \u03b111 in hypercalcemia and hypocalcemia. N Engl J Med 368:2476\u20132486","journal-title":"N Engl J Med"},{"key":"52_CR69","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1056\/NEJMc1300278","volume":"368","author":"M Mannstadt","year":"2013","unstructured":"Mannstadt M, Harris M, Bravenboer B, Chitturi S, Dreijerink KMA, Lambright DG, Lim ET, Daly MJ, Gabriel S, J\u00fcppner H (2013) Germline mutations affecting G\u03b111 in hypoparathyroidism. N Engl J Med 368:2532\u20132534","journal-title":"N Engl J Med"},{"key":"52_CR70","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.1210\/jc.2010-0651","volume":"95","author":"S Letz","year":"2010","unstructured":"Letz S, Rus R, Haag C, D\u00f6rr H-G, Schnabel D, M\u00f6hlig M, Schulze E, Frank-Raue K, Raue F, Mayr B, Sch\u00f6fl C (2010) Novel activating mutations of the calcium-sensing receptor: the calcilytic NPS 2143 mitigates excessive signal transduction of mutant receptors. J Clin Endocr Metab 95:E229\u2013E233","journal-title":"J Clin Endocr Metab"},{"key":"52_CR71","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1210\/en.2012-1887","volume":"154","author":"K Leach","year":"2013","unstructured":"Leach K, Wen A, Cook AE, Sexton PM, Conigrave AD, Christopoulos A (2013) Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators. Endocrinology 154:1105\u20131116","journal-title":"Endocrinology"},{"key":"52_CR72","doi-asserted-by":"crossref","first-page":"E1692","DOI":"10.1210\/jc.2013-1974","volume":"98","author":"A Nakamura","year":"2013","unstructured":"Nakamura A, Hotsubo T, Kobayashi K, Mochizuki H, Ishizu K, Tajima T (2013) Loss-of-function and gain-of-function mutations of calcium-sensing receptor: functional analysis and the effect of allosteric modulators NPS R-568 and NPS NPS 2143. J Clin Endocr Metab 98:E1692\u2013E1701","journal-title":"J Clin Endocr Metab"},{"key":"52_CR73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cen.12056","volume":"78","author":"SY Park","year":"2013","unstructured":"Park SY, Mun H-C, Eom YS, Baek HL, Jung TS, Kim CH, Hong S, Lee S (2013) Identification and characterization of D410E, a novel mutation in the loop 3 domain of the CaSR, in autosomal dominant hypocalcemia and a therapeutic approach using a novel calcilytic, AXT914. Clin Endocrinol 78:687\u2013693","journal-title":"Clin Endocrinol"},{"key":"52_CR74","doi-asserted-by":"crossref","first-page":"e115178","DOI":"10.1371\/journal.pone.0115178","volume":"9","author":"S Letz","year":"2015","unstructured":"Letz S, Haag C, Schulze E, Frank-Raue K, Raue F, Hofner H, Mayr B, Sch\u00f6fl C (2015) Amino alcohol- (NPS 2143) and quinazolinone-derived calcilytics (ATF936 and AXT914) differentially mitigate excessive signalling of calcium-sensing receptor mutants causing Bartter syndrome type 5 and autosomal dominant hypocalcemia. PLoS One 9:e115178","journal-title":"PLoS One"},{"key":"52_CR75","unstructured":"Babinsky VN, Hannan FM, Howles S et al. (2015) CaSR allosteric modulators rectify signal transduction abnormalities associated with G-protein alpha-11 (G\u03b111) mutations causing familial hypocalciuric hypercalcemia type 2 (FHH2) and autosomal dominant hypocalcemia type 2 (ADH2). In: 2nd International Symposium Calcium-Sensing Receptor, San Diego, CA Abst. P-029"},{"key":"52_CR76","author":"B Dong","year":"2015","unstructured":"Dong B, Endo I, Ohnishi Y, Kondo T, Hasegawa T, Amizuka N, Kiyonari H, Shioi G, Abe M, Fukumoto S, Matsumoto T (2015) Calcilytic ameliorates abnormalities of mutant calcium-sensing receptor (CaSR) knock-in mice mimicking autosomal dominant hypocalcemia (ADH). J Bone Miner Res. doi: 10.1002\/jbmr.2551","journal-title":"J Bone Miner Res"},{"key":"52_CR77","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1172\/JCI57407","volume":"122","author":"A Loupy","year":"2012","unstructured":"Loupy A, Ramakrishnan SK, Wootla B, Chambrey R, de la Faille R, Bourgeois S, Bruneval P, Mandet C, Christensen EI, Faure H, Cheval L, Laghmani K, Collet C, Eladari D, Dodd RH, Ruat M, Houillier P (2012) PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor. J Clin Invest 122:3355\u20133367","journal-title":"J Clin Invest"},{"key":"52_CR78","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1750-1172-8-97","volume":"8","author":"D Montani","year":"2013","unstructured":"Montani D, G\u00fcnther S, Dorfm\u00fcller P, Perros F, Girerd B, Ja\u00efs X, Savale L, Artaud-Macari E, Price LC, Humbert M, Simmonneau G, Sitbon O (2013) Pulmonary arterial hypertension. Orphanet J Rare Dis 8:97","journal-title":"Orphanet J Rare Dis"},{"key":"52_CR79","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/CIRCRESAHA.112.266361","volume":"111","author":"A Yamamura","year":"2012","unstructured":"Yamamura A, Guo Q, Yamamura H, Zimnicka AM, Pohl NM, Smith KA, Fernandez RA, Zeitman A, Makino A, Dong H, Yuan JX-L (2012) Enhanced Ca2+-sensing receptor function in idiopathic pulmonary arterial hypertension. Circ Res 111:469\u2013481","journal-title":"Circ Res"},{"key":"52_CR80","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1378\/chest.10-0100","volume":"138","author":"WW Busse","year":"2010","unstructured":"Busse WW (2010) The relationship of airway hyperresponsiveness and airway inflammation. Chest 138:4S\u201310S","journal-title":"Chest"},{"key":"52_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaa0282","volume":"7","author":"PL Yarova","year":"2015","unstructured":"Yarova PL, Stewart AL, Venkatachalem S et al (2015) Calcium-sensing receptor antagonists abrogate airway hyperresponsiveness and inflammation in allergic asthma. Sci Transl Med 7:1\u201311","journal-title":"Sci Transl Med"},{"key":"52_CR82","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","volume":"13","author":"WG Goodman","year":"2002","unstructured":"Goodman WG, Hladik GA, Turner SA et al (2002) The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 13:1017\u20131024","journal-title":"J Am Soc Nephrol."}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-015-0052-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-015-0052-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-015-0052-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:40:39Z","timestamp":1748594439000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-015-0052-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,30]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1007\/s00223-015-0052-z","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,30]]}}}